Aim To present the experience from collective data regarding patients with retroperitoneal sarcomas that have been operated in and followed up by the University General Hospital of Patras in Rion, Greece, between 2009 and 2020. Methods A retrospective analysis of adult patients treated at our hospital with a diagnosis of primary retroperitoneal sarcoma who underwent tumour resection. Results Data from 29 patients were analysed. The mean age at diagnosis was 56.1 years; 55.2% of patients were male (n=16). Liposarcomas (on histology) were identified in 19 (65.5%) patients, leiomyosarcoma six (20.7%), and other histologic subtypes in four (13.8%) patients. Tumours >5cm were presented in 27 (93.1%) patients. Negative margins were attained in 13 (44.8%) of all patients who underwent surgical resection. Five (17.2%) patients received neoadjuvant radiation, four (13.8%) postoperative radiation, and three (10.3%) patients received both chemotherapy and radiation prior to surgery with the rest of the patients being treated with surgical excision alone. A 3-year follow-up was successful in 21 (72.4%) patients; five (23.8%) patients died. In total, 16 (55.2%) patients were found to have a local recurrence, with no significant difference in patients' age, gender, tumour size, histology, negative surgical margin (Ro) resection, neoadjuvant chemotherapy, or radiation therapy. There was a significant difference in the 3-year survival rate between patients having positive or negative surgical margins (p=0.027). Conclusion The higher 3-year survival rate in patients with retroperitoneal sarcomas when achieving Ro resection warrant further investigation with a larger sample size across different institutions.
Fairweather M, Raut C. Nephrectomy for retroperitoneal sarcoma: stay calm and (cautiously) carry on. Ann Surg Oncol 2021:1275–7.
2
Gyorki D, Brennan M. Management of recurrent retroperitoneal sarcoma. J Surg Oncol 2014:53–9.
3
Gronchi A, Strauss D, Miceli R, Bonvalot S, Swallow C, Hohenberger P, et al. Variability in patterns of recurrence after resection of primary retroperitoneal sarcoma (RPS): a report on 1007 patients from the multi-institutional Collaborative RPS Working Group. Ann Surg 2016:1002–9.
4
Van Houdt W, Zaidi S, Messiou C, Thway K, Strauss D, Jones R. Treatment of retroperitoneal sarcoma: current standards and new developments. Curr Opin Oncol 2017:260–7.
5
Garcia-Ortega D, Villa-Zepeda O, Martinez-Said H, Cuellar-Hübbe M, Ortiz L, K. Oncology outcomes in retroperitoneal sarcomas: prognostic factors in a retrospective cohort study. Int J Surg 2016:45–9.
6
Novak M, Perhavec A, Povšic K, Arnuš M, Eržen M, D. Primary localized retroperitoneal sarcomas: report from Slovenian sarcoma referral center. World J Surg Oncol 2020:277.
7
Giuliano K, Nagarajan N, Canner J, Wolfgang C, Bivalacqua T, Terezakis S, et al. Predictors of improved survival for patients with retroperitoneal sarcoma. Surgery 2016:1628–35.
8
Callegaro D, Miceli R, Gladdy R. Prognostic models for RPS patients-attempting to predict patient outcomes. J Surg Oncol 2018:69–78.
9
Mulita F, Oikonomou N, Tchabashvili L, Liolis E, Kehagias I. A giant ovarian mucinous tumor in a 58-year-old postmenopausal patient with persistent abdominal pain and high serum levels of CA 19-9. Pan Afr Med J 2020:76.
10
Fairweather M, Gonzalez R, Strauss D, Raut C. Current principles of surgery for retroperitoneal sarcomas. J Surg Oncol 2018:33–41.
11
Mulita F, Liolis E, Kehagias D, Tchabashvili L, Kaplanis C, Iliopoulos F, et al. An enormous pelvic tumor in a 46-year-old woman with an elevated serum CA 125 level, what lies beneath it? Investigation of uterine tumors in postmenopausal women. Prz Menopauzalny 2021:154–7.
12
Mulita F, Iliopoulos F, Kehagias I. A rare case of gastric-type mucinous endocervical adenocarcinoma in a 59-year-old woman. Prz Menopauzalny 2020:147–50.
13
Tyler R, Lee M, Ierodiakonou V, Hodson J, Taniere P, Almond M, et al. Prognostic implications of histological organ involvement in retroperitoneal sarcoma. BJS Open 2021:80.
14
Nussbaum D, Rushing C, Lane W, Cardona D, Kirsch D, Peterson B. Blazer DG 3rd. Preoperative or postoperative radiotherapy versus surgery alone for retroperitoneal sarcoma: a case-control, propensity score-matched analysis of a nationwide clinical oncology database. Lancet Oncol 2016:966–75.
15
Berger N, Silva J, Mogal H, Clarke C, Bedi M, Charlson J, et al. Overall survival after resection of retroperitoneal sarcoma at academic cancer centers versus community cancer centers: An analysis of the National Cancer Data Base. Surgery 2018:318–23.
16
Liles J, Tzeng C, Short J, Kulesza P, Heslin M. Retroperitoneal and intra-abdominal sarcoma. Curr Probl Surg 2009:445–503.
17
Du G, Zhang Z, Wen X, Yu C, Calway T, Yuan C, et al. Epigallocatechin Gallate (EGCG) is the most effective cancer chemopreventive polyphenol in green tea. Nutrients 2012:1679–91.
18
Kwong M, Lee B, Kunihira K, Sutjiadi B, Reeves M, Selleck M, et al. Treatment factors associated with overall survival in retroperitoneal sarcoma: an institutional review. Am Surg 2020:1358–62.
19
Macneill A, Van Houdt W, Swallow C, Gronchi A. Management of metastatic retroperitoneal sarcoma: a consensus approach from the Trans-Atlantic Retroperitoneal Sarcoma Working Group (TARPSWG). Ann Oncol 2018:857–71.
20
Ma S, Oladeru O, Farrugia M, Shekher R, Iovoli A, Singh A. Evaluation of preoperative chemotherapy or radiation and overall survival in patients with nonmetastatic, resectable retroperitoneal sarcoma. JAMA Netw Open 2020.
21
Livingston J, Bugano D, Barbo A, Lin H, Madewell J, Wang W, et al. Role of chemotherapy in dedifferentiated liposarcoma of the retroperitoneum: defining the benefit and challenges of the standard. Sci Rep 2017:11836.
22
Almond L, Gronchi A, Strauss D, Jafri M, Ford S, Desai A. Neoadjuvant and adjuvant strategies in retroperitoneal sarcoma. Eur J Surg Oncol 2018:571–9.
23
Constantinidou A, Jones R. Systemic therapy in retroperitoneal sarcoma management. J Surg Oncol 2018:87–92.
24
Seidensaal K, Kieser M, Hommertgen A, Jaekel C, Harrabi S, Herfarth K, et al. Neoadjuvant irradiation of retroperitoneal soft tissue sarcoma with ions (Retro-Ion): study protocol for a randomized phase II pilot trial. Trials 2021:134.
25
Sargos P, Stoeckle E, De Figueiredo H, Antoine B, Delannes M, Mervoyer M, et al. Radiotherapy for retroperitoneal sarcomas. Cancer Radiother 2016:677–84.
26
Shiraev T, Pasricha S, Choong P, Schlicht S, Van Rijswijk C, Dimmick S, et al. Retroperitoneal sarcomas: a review of disease spectrum, radiological features, characterisation and management. J Med Imaging Radiat Oncol 2013:687–700.
27
Tattersall H, Callegaro D, Ford S, Gronchi A. Staging, nomograms and other predictive tools in retroperitoneal soft tissue sarcoma. Chin Clin Oncol 2018:36.
28
Sassa N. Retroperitoneal tumors: review of diagnosis and management. Int J Urol 2020:1058–70.
29
Carbone F, Pizzolorusso A, Lorenzo D, G, Marzo D, Cannella M, et al. Multidisciplinary management of retroperitoneal sarcoma: diagnosis, prognostic factors and treatment. Cancers (Basel) n.d.:4016.
30
Mulita F, Mukkamalla S. Lymph Node Dissection. StatPearls [Internet]. Treasure Island (FL) 2022.
31
Mulita F, Verras G, Liolis E, Tchabashvili L, Kehagias D, Kaplanis C, et al. Recurrent retroperitoneal liposarcoma: a case report and literature review. Clin Case Rep 2021:4717.
Matthyssens L, Creytens D, Ceelen W. Retroperitoneal liposarcoma: current insights in diagnosis and treatment. Front Surg 2015:4.
34
Vijay A, Ram L. Retroperitoneal liposarcoma: a comprehensive review. Am J Clin Oncol 2015:213–9.
35
Guzzo T, Malkowicz B, S. Retroperitoneal diseases. Penn Clin Man Urol 2007:653–64.
36
Mulita F, Lampropoulos C, Kehagias D, Verras G, Tchabashvili L, Kaplanis C, et al. Long-term nutritional deficiencies following sleeve gastrectomy: a 6-year singlecentre retrospective study. Prz Menopauzalny 2021:170–6.
37
Messiou C, Moskovic E, Vanel D, Morosi C, Benchimol R, Strauss D, et al. Primary retroperitoneal soft tissue sarcoma: Imaging appearances, pitfalls and diagnostic algorithm. Eur J Surg Oncol 2017:1191–8.
38
Crowe P. A retroperitoneal mass needs respect. ANZ J Surg 2018:261–2.
39
Mullinax J, Zager J, Gonzalez R. Current diagnosis and management of retroperitoneal sarcoma. Cancer Control 2011:177–87.
40
Gyorki D, Choong P, Slavin J, Henderson M. Importance of preoperative diagnosis for management of patients with suspected retroperitoneal sarcoma. ANZ J Surg 2018:274–7.
41
Messiou C, Morosi C. Imaging in retroperitoneal soft tissue sarcoma. J Surg Oncol 2018:25–32.
42
Mulita F, Parchas N, Germanos S, Papadoulas S, Maroulis I. Case report of a local recurrence of spindle cell embryonal rhabdomyosarcoma. Med Arch 2020:240–2.
43
Van Houdt W, Schrijver A, Cohen-Hallaleh R, Memos N, Fotiadis N, Smith M. Needle tract seeding following core biopsies in retroperitoneal sarcoma. Eur J Surg Oncol 2017:1740–5.
44
Kirane A, Crago A. The importance of surgical margins in retroperitoneal sarcoma. J Surg Oncol 2016:270–6.
45
Stahl J, Corso C, Park H, Rutter A, Han C, Roberts D, et al. The effect of microscopic margin status on survival in adult retroperitoneal soft tissue sarcomas. Eur J Surg Oncol 2017:168–74.
46
Wang J, Grignol V, Gronchi A, Luo C, Pollock R, Tseng W. Surgical management of retroperitoneal sarcoma and opportunities for global collaboration. Chin Clin Oncol 2018:39.
47
Pham V, Henderson-Jackson E, Doepker M, Caracciolo J, Gonzalez R, Druta M, et al. Practical issues for retroperitoneal sarcoma. Cancer Control 2016:249–64.
48
Fevre C Le, Waissi W, Chambrelant I, Noel G, Antoni. A critical narrative review of radiotherapy for retroperitoneal soft tissue sarcoma. Chinese Clin Oncol 2020:79.
49
Trovik L, Ovrebo K, Almquist M, Haugland H, Rissler P, Eide J, et al. Adjuvant radiotherapy in retroperitoneal sarcomas. A Scandinavian Sarcoma Group study of 97 patients. Acta Oncol 2014:1165–72.
50
Bonvalot S, Gronchi A, Péchoux L, Swallow C, Strauss C, Meeus D, et al. Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label. Lancet Oncol 2020:1366–77.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
,
